Journal
CANCER LETTERS
Volume 541, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2022.215750
Keywords
Immunotherapy; Immune infiltration; ASO; PD-L1; HCC
Categories
Ask authors/readers for more resources
This research explores the immunoregulatory function of metadherin (MTDH) in hepatocellular cancer (HCC), and demonstrates that MTDH can modulate PD-L1 expression and transcriptional activity through the β-catenin/LEF-1 signaling pathway. Moreover, combining MTDH ASO with PD-1 mAb improves the effectiveness of immune checkpoint blockade therapy and increases infiltration of cytotoxic T cells. MTDH may serve as a potential biomarker for predicting the therapeutic efficacy of immune checkpoint inhibitor treatment.
Immune checkpoint blockade (ICB) therapy is an important treatment option for individuals with cancer, but it has certain limitations. Identifying a better target that can overcome tumor immune escape and stimulate T cell activity is critical. This research aimed to delve into the molecular mechanism underlying the immunoregulatory function of metadherin (MTDH), which is a novel and potential therapeutic target in hepatocellular cancer (HCC). A small interfering RNA library was screened using the luciferase reporter assay and PD-L1 promoter. The Cancer Genome Atlas database and HCC tissues were used to investigate the relationship between MTDH and PDL1. The association between MTDH and beta-catenin/lymphoid enhancer binding factor (LEF-1) was discovered by co-immunoprecipitation. The chromatin immunoprecipitation assay was used to investigate the interaction of MTDH with the PD-L1 promoter when LEF-1 expression was silenced. Locked nucleic acid antisense oligonucleotides (ASOs) were used to inhibit MTDH. We utilized in vitro co-cultures and in vivo syngeneic tumor development experiments to confirm the effectiveness of MTDH ASO combined with PD-1 monoclonal antibody (mAb). MTDH was demonstrated to be a PD-L1 modulator. MTDH increased PD-L1 expression and upregulated PD-L1 transcriptional activity through beta-catenin/LEF-1 signaling. More importantly, MTDH ASO improved the anti-PD-1 response and increased cytotoxic T-cell infiltration in PD-1 mAb-treated malignancies. MTDH effectively predicts the therapeutic efficacy of ICB therapy. Our results imply that combining MTDH ASO with PD-1 mAb could be a promising therapeutic strategy for HCC. In addition, MTDH is a potential novel biomarker for predicting the effectiveness of immune checkpoint inhibitor treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available